JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
USDÂ 232,67
arrow_upward
+0,55%(+1,28) 1D
7 Okt., 15:14:53 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for JAZZ...
Open
USDÂ 229,62
High
USDÂ 235,54
Low
USDÂ 227,00
Mkt. cap
15,10Â mjd
Avg. vol.
1,01Â m
Volume
260,18Â k
P/E ratio
15,91
52-wk high
USDÂ 266,38
52-wk low
USDÂ 128,80
EPS
USDÂ 14,63
Beta
0,37
Shares outstanding
64,92Â m
No. of employees
3Â k
Open
USDÂ 229,62
High
USDÂ 235,54
Low
USDÂ 227,00
Mkt. cap
15,10Â mjd
Avg. vol.
1,01Â m
Volume
260,18Â k
P/E ratio
15,91
52-wk high
USDÂ 266,38
52-wk low
USDÂ 128,80
EPS
USDÂ 14,63
Beta
0,37
Shares outstanding
64,92Â m
No. of employees
3Â k
News stories
From web sources and news partners
Zacks
·
1 dag gelede
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Profile
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
About Jazz Pharmaceuticals PLC
CEOBruce C Cozadd
Employees2,89Â k
Founded2003
Headquarters-
SectorPharmaceutical industry
Websitejazzpharma.com